Lipocine (NASDAQ:LPCN) Stock Price Passes Below Two Hundred Day Moving Average – Should You Sell?

Lipocine Inc. (NASDAQ:LPCN)’s share price crossed below its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $4.17 and traded as low as $2.05. Lipocine shares last traded at $2.05, with a volume of 24,869 shares traded.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on the company. Wall Street Zen raised Lipocine from a “sell” rating to a “hold” rating in a research report on Saturday, July 18th. Weiss Ratings upgraded Lipocine from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday. One analyst has rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Reduce” and an average target price of $15.00.

Lipocine Price Performance

The stock’s fifty day simple moving average is $2.25 and its 200-day simple moving average is $4.10. The firm has a market cap of $17.22 million, a PE ratio of -1.17 and a beta of 0.46.

Lipocine (NASDAQ:LPCN) last released its earnings results on Tuesday, August 4th. The specialty pharmaceutical company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.40) by $0.08. The firm had revenue of $0.19 million for the quarter, compared to the consensus estimate of $0.21 million. Lipocine had a negative return on equity of 64.75% and a negative net margin of 755.39%. Analysts expect that Lipocine Inc. will post -1.91 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the company. Citadel Advisors LLC purchased a new stake in Lipocine in the third quarter valued at approximately $41,000. Jane Street Group LLC acquired a new position in Lipocine in the 4th quarter worth approximately $85,000. Dimensional Fund Advisors LP raised its position in Lipocine by 57.5% during the 1st quarter. Dimensional Fund Advisors LP now owns 19,122 shares of the specialty pharmaceutical company’s stock worth $153,000 after buying an additional 6,982 shares during the last quarter. ADAR1 Capital Management LLC acquired a new stake in Lipocine during the 1st quarter valued at approximately $185,000. Finally, Renaissance Technologies LLC lifted its stake in Lipocine by 3.6% during the 4th quarter. Renaissance Technologies LLC now owns 37,397 shares of the specialty pharmaceutical company’s stock valued at $300,000 after acquiring an additional 1,300 shares during the period. 9.11% of the stock is currently owned by hedge funds and other institutional investors.

About Lipocine

Lipocine Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of oral drug delivery technologies. The company’s core expertise lies in lipid-based formulations designed to improve the bioavailability of therapeutics that traditionally require injectable administration. By leveraging proprietary technologies, Lipocine aims to offer patient-friendly alternatives with the potential for more consistent pharmacokinetic profiles and improved compliance.

The company’s lead product, TLANDO (LPCN 1021), is an oral testosterone replacement therapy approved by the U.S.